IPHARMA continue to hold a series of webinars in order to provide information to the vast media audience on various aspects of clinical trials conduct.
The article on the results of clinical trial CV-TRX-01 "New Russian anticoagulant Xa factor inhibitor group Tiareksaban" has been published in the journal "Thrombosis, Hemostasis and rheology" № 4 (64).
The report of IPHARMA Chief Operating Officer Natalia Vostokova at the Global conference DIA 2016 28th Annual EuroMeeting in Hamburg.
Safe use of drugs is one of the main priorities of a modern healthcare system. According to the World Health Organization, adverse drug reactions (side effects) are in the top ten leading causes of death in many countries.
Comparison of the novel Russian DPP-4 inhibitor gosogliptin with vildagliptin in patients with type 2 diabetes mellitus
Results of the Phase III clinical trial of a novel DPP-4 inhibitor Gosogliptin were published in the journal "Diabetes mellitus" 19 (1) 2016. The adaptive two-stage design had been applied to the trial, which allowed evaluating the efficacy and safety of gosogliptin for use as monotherapy and in combination with metformin.
Results of a 24-week study of the efficacy and safety of a new domestic NNRTI (VM-1500, Elpvirin) compared to EFV as a part of ARVT treatment setting in HIV-1 infected Tx naпve patients
Results of IPHARMA clinical trial HIV-VM1500-04 of Elpida were presented at the VIII Annual Russian Congress with international participation on Infectious Diseases.
Interim results of IPHARMA clinical trial of the "DNA-4" vaccine were presented at the Fifth Eastern Europe and Central Asia AIDS Conference (EECAAC 2016).